<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02224144</url>
  </required_header>
  <id_info>
    <org_study_id>AAAM7850</org_study_id>
    <nct_id>NCT02224144</nct_id>
  </id_info>
  <brief_title>Bone Mass and Strength After Kidney Transplantation</brief_title>
  <official_title>A Comparative Trial of Calcitriol Versus Placebo for the Preservation of Bone Mass and Strength After Kidney Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Satellite Healthcare</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test whether active vitamin D (calcitriol) protects bones
      from weakening and protects blood vessels from calcium deposits over the first year of kidney
      transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Kidney transplant recipients at highest fracture risk, as determined by epidemiologic studies
      (Caucasians and older recipients). Rocaltrol (calcitriol) is a synthetic vitamin D analog
      which is active in the regulation of the absorption of calcium from the gastrointestinal
      tract and its utilization in the body.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in bone quality from pre to post-calcitriol treatment compared to placebo as assessed by both standard methodologies.</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>Novel high resolution bone imaging can separately measure and quantify cortical and trabecular responses to bone active treatments. Finite element analysis (FEA) can be applied to HRpQCT datasets. to provide a computational estimate of bone mechanical competence that has been validated against true compressive tests of bone stiffness and strength.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Areal and Volumetric Bone Mass Density from baseline to 12 months after transplantation</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>Apply imaging methods to shed light on whether preservation of areal bone mineral density (BMD) measured by dual-energy x-ray absorptiometry (DXA) is accompanied by preservation of bone mechanical competence measured by a method that has been validated against true compressive tests of bone strength.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in cortical and trabecular bone strength pre- and post-transplantation measured by high resolution imaging methods.</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>Apply advanced imaging methods to determine the influence of calcitriol on cortical and trabecular microarchitecture and strength after kidney transplantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent contribution of cortical porosity to mechanical competence pre- and post-intervention measured by Cortical Porosity Assessment techniques.</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>Apply Cortical Porosity Assessment techniques to high resolution peripheral quantitative computed tomography (HRpQCT) scans to quantify the contribution of cortical porosity to mechanical competence in kidney transplant patients both pre- and post-calcitriol treatment compared to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline to 12 months on vascular calcifications loads of the lower extremity</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>Measured by a novel method applied to HRpQCT datasets.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with vascular calcifications of the lower extremity</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>Quantification of calcifications of the anterior and posterior tibia arteries measured by a novel method applied to HRpQCT at baseline and 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pre- and post- intervention parathyroid hormone (PTH) levels at baseline,1 month and 12 months after transplantation.</measure>
    <time_frame>Baseline, 1month, 12 months</time_frame>
    <description>Determine effects of calcitriol on post-transplantation PTH.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pre- and post- intervention levels of bone remodeling markers for bone remodeling assessment from baseline to 1 month and 12 months after transplantation.</measure>
    <time_frame>Baseline, 1 month, 12 months</time_frame>
    <description>Determine effects of calcitriol on post-transplantation bone remodeling markers.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>End Stage Renal Disease</condition>
  <condition>Kidney Transplantation</condition>
  <condition>Bone Loss</condition>
  <condition>Fractures</condition>
  <condition>Vascular Calcifications</condition>
  <arm_group>
    <arm_group_label>Vitamin D3 plus Calcitriol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 pill of Vitamin D3 (cholecalciferol) 1000 IU daily for 12 months
1 pill of Rocaltrol (calcitriol) 0.5 mcg daily for 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D3 plus Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 pill of Vitamin D3 (cholecalciferol) 1000 IU per day for 12 months
1 pill of placebo (sugar pill) per day for 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>Vitamin D3 1000 IU per day for 12 months</description>
    <arm_group_label>Vitamin D3 plus Calcitriol</arm_group_label>
    <arm_group_label>Vitamin D3 plus Placebo</arm_group_label>
    <other_name>cholecalciferol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcitriol</intervention_name>
    <description>Calcitriol (Rocaltrol) 0.5 mcg per day for 12 months</description>
    <arm_group_label>Vitamin D3 plus Calcitriol</arm_group_label>
    <other_name>Rocaltrol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (sugar pill) 1 pill per day for 12 months</description>
    <arm_group_label>Vitamin D3 plus Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age older than 18

          -  Self-describes as White race

        Exclusion Criteria:

          -  Lower extremity amputations

          -  Non-ambulatory

          -  PagetÂ´s disease of bone

          -  Current hyperthyroidism, untreated hypothyroidism

          -  Medical diseases (end stage liver, intestinal malabsorption)

          -  Use within the prior year pod anti-seizure medications that induce the cytochrome P450
             system, testosterone, estrogen, selective estrogen receptor modulators

          -  Weight &gt;300 pounds

          -  Dual organ transplant

          -  Myocardial infarction or stroke

          -  Tobacco use within the past year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Nickolas, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Iyer SP, Nikkel LE, Nishiyama KK, Dworakowski E, Cremers S, Zhang C, McMahon DJ, Boutroy S, Liu XS, Ratner LE, Cohen DJ, Guo XE, Shane E, Nickolas TL. Kidney transplantation with early corticosteroid withdrawal: paradoxical effects at the central and peripheral skeleton. J Am Soc Nephrol. 2014 Jun;25(6):1331-41. doi: 10.1681/ASN.2013080851. Epub 2014 Feb 7.</citation>
    <PMID>24511131</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 22, 2014</study_first_submitted>
  <study_first_submitted_qc>August 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2014</study_first_posted>
  <last_update_submitted>July 18, 2017</last_update_submitted>
  <last_update_submitted_qc>July 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Thomas Nickolas</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Kidney Transplantation</keyword>
  <keyword>Calcitriol</keyword>
  <keyword>Bone Mineral Density</keyword>
  <keyword>Bone Mass and Strength</keyword>
  <keyword>Vascular Calcifications</keyword>
  <keyword>Hyperparathyroidism</keyword>
  <keyword>Parathyroid Hormone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Calcinosis</mesh_term>
    <mesh_term>Vascular Calcification</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Calcitriol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

